NCT05223829View on ClinicalTrials.gov

Utility of Brexanolone to Target Stress-induced Alcohol Use Among Men and Women With Posttraumatic Stress Disorder

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

August 1, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
PTSDAlcohol Use Disorder
Interventions
DRUG

Brexanolone

Brexanolone will be administered as a continuous IV infusion over 20 hours under medical observation

Trial Locations (1)

06519

Yale School of Medicine, New Haven

Sponsors

Collaborators (1)

Sage Therapeutics
All Listed Sponsors
collaborator

National Institute on Alcohol Abuse and Alcoholism (NIAAA)

NIH

collaborator

Sage Therapeutics

INDUSTRY

lead

Yale University

OTHER

NCT05223829 - Utility of Brexanolone to Target Stress-induced Alcohol Use Among Men and Women With Posttraumatic Stress Disorder | Biotech Hunter | Biotech Hunter